REGN7508 for Prevention of Cancer-Associated Thrombosis
Research type
Research Study
Full title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)
IRAS ID
1012462
Contact name
Bolar Adenuga
Contact email
Sponsor organisation
Regeneron Pharmaceuticals Inc.
Research summary
This study is researching an experimental drug called REGN7508 (called “study drug”). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
• What side effects may happen from taking the study drug
• How much study drug is in the blood at different times
• Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)REC name
East of England - Cambridge East Research Ethics Committee
REC reference
26/EE/0019
Date of REC Opinion
23 Feb 2026
REC opinion
Further Information Favourable Opinion